Page last updated: 2024-08-16

tetraethylammonium and s 1033

tetraethylammonium has been researched along with s 1033 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Eadie, L; Hughes, TP; White, DL	1

Other Studies

1 other study(ies) available for tetraethylammonium and s 1033

Article	Year
Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia, 2010, Volume: 24, Issue:4 Topics: Adrenergic alpha-Antagonists; Benzamides; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Piperazines; Prazosin; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tetraethylammonium; Tumor Cells, Cultured	2010

Article

Year

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells.

Leukemia, 2010, Volume: 24, Issue:4

Topics: Adrenergic alpha-Antagonists; Benzamides; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Piperazines; Prazosin; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tetraethylammonium; Tumor Cells, Cultured

2010